Camp4 Therapeutics (CAMP) Registration filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on regulatory RNA-based therapeutics to upregulate gene expression for genetic diseases.

• Proprietary RNA Actuating Platform (RAP) enables identification and targeting of regulatory RNAs (regRNAs) to modulate gene expression.

• Lead programs target metabolic and CNS disorders, with initial focus on urea cycle disorders (UCDs) and SYNGAP1-related disorders.

• Retains exclusive, worldwide rights to all product candidates and discovery programs.

Financial performance and metrics

• Net losses of $49.3M in 2023 and $25.0M for the six months ended June 30, 2024; accumulated deficit of $185.0M as of June 30, 2024.

• Cash and cash equivalents of $12.6M as of June 30, 2024.

• No product revenue to date; revenue to date from license and collaboration agreements.

• Research and development expenses were $40.6M in 2023 and $19.1M for the first half of 2024.

• Independent auditor expressed substantial doubt about ability to continue as a going concern.

Use of proceeds and capital allocation

• Net proceeds intended to fund clinical development of CMP-CPS-001 for UCDs, advance CMP-SYNGAP for SYNGAP1-related disorders, expand the RAP Platform, and for working capital and general corporate purposes.

• Proceeds will not be sufficient to fund any product candidate through regulatory approval; additional capital will be required.